All News
Filter News
Found 808,963 articles
-
IBEX Reports Results for the Third Quarter and the Nine Months Ended April 30, 2023
6/7/2023
IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the third quarter and the nine months ended April 30, 2023.
-
Actinium Pharma Set to Join Russell 2000® and Russell 3000® Indexes
6/7/2023
Actinium Pharmaceuticals, Inc. announced that it will be added as a member of the small-cap Russell 2000® and all-cap Russell 3000® Indexes as part of the 2023 Russell indexes reconstitution, according to a preliminary list of additions posted May 19 and effective upon the U.S. market close on June 23, 2023.
-
Vera Therapeutics Initiates Pivotal Phase 3 (ORIGIN 3) Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (IgAN)
6/7/2023
Vera Therapeutics, Inc. today announced initiation of the pivotal Phase 3 clinical trial (ORIGIN 3) of atacicept for the treatment of IgA nephropathy (IgAN).
-
Retinalgenix Technologies, Inc. Expands Team to Hasten the Launch of DNA/GPS
6/7/2023
RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), announced today the hiring of Owen Watson, MS.
-
Inari Medical Announces Commercial Launch of RevCore™ and Triever16 Curve™, Two New Purpose-Built Products for Addressing Venous Stent Thrombosis and Venous Thromboembolism
6/7/2023
Inari Medical, Inc. announced the launch of two new purpose-built products, the RevCore thrombectomy catheter, and the Triever16 Curve catheter.
-
eFFECTOR Therapeutics Announces $8.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6/7/2023
eFFECTOR Therapeutics, Inc. today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of an aggregate of 7,764,445 shares of its common stock.
-
Trinity Life Sciences Names Leslie Orne as Next Chief Executive Officer
6/7/2023
Trinity Life Sciences announced today the appointment of Leslie Orne as Chief Executive Officer (CEO) effective July 1.
-
SASKATOON-BASED BIOPHARMA COMPANY MED-LIFE DISCOVERIES RECEIVES NO OBJECTION LETTER FROM HEALTH CANADA TO BEGIN A HEALTHY ADULT PHASE 1 TRIAL FOR PPI-1011
6/7/2023
Med-Life Discoveries, LP (“MLD”, or the “Company”), is a Canadian biopharmaceutical company dedicated to advancing a therapy to reduce symptoms for a devastating pediatric rare disease, Rhizomelic chondrodysplasia punctata (RCDP),
-
LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE’s Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas
6/7/2023
LIXTE Biotechnology Holdings, Inc. today announced the enrollment of the first patient in the Phase 1b portion of the Phase 1b/2 protocol (NCT05809830 ) to determine the appropriate dose of LB-100 given with a standard dose of doxorubicin.
-
SpectronRx and RLS Team Up to Enhance the Radiopharmaceutical Pipeline and Supply Chain
6/7/2023
SpectronRx, a leading radiopharmaceutical developer and manufacturer, and RLS (Radioisotope Life Sciences) Inc., the third-largest nuclear medicine pharmacy network in the US, today announced an agreement that will significantly enhance the supply and availability of diagnostic and therapeutic radiopharmaceuticals.
-
Forward Pharma A/S Announces Change in Ratio of American Depositary Shares to Ordinary Shares
6/7/2023
Forward Pharma A/S (OTC:FWPAY) (“Forward” or the “Company”) today announced that its Board of Directors has approved a change in the number of its ordinary shares represented by American Depositary Shares (“ADSs”), issued by the Bank of New York Mellon as depositary, from 14 ordinary shares per ADS to 4000 ordinary shares per ADS.
-
Breakthrough results announced: Nelson biotech start-up Kimer Med confirms its antiviral compound's effectiveness against two priority viruses, bringing total to seven.
6/7/2023
Kimer Med, a Nelson, New Zealand-based biotech start-up developing broad-spectrum antiviral compounds, today announced that it had achieved two 100% positive results in tests against the priority viruses Dengue (DENV-2) and Zika (ZIKV).
-
BeyondSpring and Leading Cancer Center Present Poster Highlighting Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCTData Presented at 2023 ASCO Annual Meeting
6/7/2023
BeyondSpring Inc. today announced new data from a Phase 1 investigator initiated study highlighting a reduction in chemotherapy-induced infectious neutropenic fever with lead asset Plinabulin in combination with pegfilgrastim in multiple myeloma (MM) patients who underwent autologous hematopoietic stem cell transplantation (AHCT) and received a high dose of melphalan, a type of chemotherapy and one of the most active treatments for MM (NCT05130827).
-
DTx Pharma Receives FDA Orphan Drug Designation for DTx-1252 for the Treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A)
6/7/2023
DTx Pharma today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to DTx-1252.
-
Mozart Therapeutics Raises $25 Million in Expanded Series A Financing to Support Clinical Development of First-in-Class CD8 Treg Modulators for the Treatment of Autoimmune Diseases
6/7/2023
Mozart Therapeutics today announced it has raised $25 million from new investors in a Series A extension, bringing the total raise to $80 million.
-
Rigel Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML
6/7/2023
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced promising data from an analysis of the Phase 2 study evaluating REZLIDHIA® (olutasidenib), a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase-1 (mIDH1)1, in patients with mIDH1 acute myeloid leukemia (AML) who were relapsed/refractory (R/R) to prior venetoclax-based regimens.
-
Optimized for Crossing Venous and Arterial Occlusions: Tunnel™ Crossing Catheter Receives US FDA 510(k) Clearance
6/7/2023
Tractus Vascular, LLC today announced 510(k) clearance of the Tunnel™ Crossing Catheter (Tunnel™ CC).
-
4DMT Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at the ECFS 46th Annual Meeting
6/7/2023
4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company) today announced positive interim clinical data from the 4D-710 Phase 1/2 AEROW clinical trial for the treatment of cystic fibrosis lung disease.
-
Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials
6/7/2023
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX) today reported initial proof of concept monotherapy data from its Phase 1 MYTHIC clinical trial evaluating lunresertib (RP-6306), a first-in-class, oral PKMYT1 inhibitor in molecularly selected advanced solid tumors.
-
MAIA Biotechnology Files Second Patent For New Telomere-Targeting Molecules Program
6/7/2023
MAIA Biotechnology, Inc. (NYSE American: MAIA ) today announced its second broad provisional patent application covering the composition of matter for a new telomere-targeting molecule.